Oral calcium effectively reduces parathyroid hormone levels in hemodialysis patients: a randomized double-blind placebo-controlled study.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Nephron

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000187515PMID 8289986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.

  1992cited by this paper
• Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.

  1991cited by this paper
• Effects on serum parathyroid hormone of intravenous treatment with alphacalcidol in patients on chronic hemodialysis.

  1990cited by this paper
• Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol.

  1990cited by this paper
• Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure.

  1989cited by this paper
• Effect of intravenous 1-alpha-hydroxyvitamin D3 on secondary hyperparathyroidism in chronic uremic patients on maintenance hemodialysis.

  1989cited by this paper
• Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.

  1989cited by this paper
• High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.

  1989cited by this paper
• Long-term effect of low calcium dialysate on parathyroid activity in dialysis patients treated with calcium carbonate as a phosphate binder.

  1989cited by this paper
• Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.

  1989cited by this paper
• Suppression of serum parathyroid hormone levels by intravenous alphacalcidol in uremic patients on maintenance hemodialysis. A pilot study.

  1988cited by this paper
• Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure.

  1988cited by this paper
• Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia.

  1987cited by this paper
• Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure.

  1987cited by this paper
• Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.

  1986cited by this paper
• Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.

  1986cited by this paper
• Controlled trial of calcitriol in hemodialysis patients.

  1986cited by this paper
• Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.

  1985cited by this paper
• Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

  1984cited by this paper
• Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperaluminaemia and equal control of hyperparathyroidism.

  1983cited by this paper
• Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis.

  1981cited by this paper
• 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.

  1978cited by this paper
• Jejunal and ileal absorption in patients with chronic renal disease. Effect of 1alpha-hydroxycholecalciferol.

  1976cited by this paper
• 1,25 Dihydroxy-vitamin D3 in normal man and patients with renal failure.

  1974cited by this paper
• The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure.

  1966cited by this paper

• Efficacy and Safety of Phosphate-Lowering Agents for Adult Patients with CKD Requiring Dialysis

  2025cites this paper
• Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

  2025cites this paper
• Recommended calcium intake in adults and children with chronic kidney disease - a European consensus statement.

  2023cites this paper
• 52 Medical Management of Parathyroid Disease

  2021cites this paper
• Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).

  2018cites this paper
• Hyperphosphatemia Management in Patients with Chronic Kidney Disease

  2015cites this paper
• 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.

  2008cites this paper
• Clinical studies on prophylaxis and treatment of cedondary hyperparathyroidism in uremic patients on chronic dialysis

  2008cites this paper
• Renal Osteodystrophy: Pathogenic Mechanisms and Therapeutic Options

  2008cites this paper
• Fresh®, Calcigamma®, Calcilos®, Calcimax®, Calcit®, calcitonin, Calcitridin®, calcitriol, calcium acetate, calcium aspartate, calcium carbonate, calcium chelate, calcium chloride, calcium citrate, calcium citrate malate, Calcium Dago® (Germany), calcium formate, calcium glucepate, calcium gluconate,

  2007cites this paper
• Control of Parathyroid Function in Patients with a Short History of Hemodialysis

  2005cites this paper
• Calcium agonists in hyperparathyroidism

  2004cites this paper
• The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.

  2003cites this paper
• Renal osteodystrophy

  2002cites this paper
• Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.

  2000cites this paper
• Large, rapid skeletal changes after parathyroidectomy.

  1997cites this paper
• Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.

  1996cites this paper
• Combined measurements of ionized calcium and intact parathyroid hormone in blood.

  1996cites this paper
• Effect of 1,25-dihydroxyvitamin D on the immune activity of peritoneal macrophages in continuous ambulatory peritoneal dialysis patients.

  1995cites this paper
• Effect of oral calcium on noninvasive indices of bone formation and bone mass in hemodialysis patients: a randomized double-blind placebo-controlled study.

  1994cites this paper
• Long-Term Oral Calcium Supplementation Reduces Diastolic Blood Pressure in End Stage Renal Disease. A Randomized, Double-Blind, Placebo Controlled Study

  1994cites this paper